Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.33 |
| ▸ | AXL | P30530 | 3/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.30 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.30 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5518881 | 0.93 | AAK1 (0.33) | AAK1AXLIDO1MAP4K4PDPK1 | |
| SCHEMBL5506720 | 0.92 | MET (0.33) | AAK1AXLIDO1MAP4K4PDPK1 | |
| SCHEMBL14437271 | 0.87 | CISD1 (0.39) | FLT3AAK1BRD4MAP4K4CISD1 | |
| SCHEMBL5518997 | 0.86 | PDGFRA (0.39) | AAK1AXLMET | |
| SCHEMBL5506278 | 0.81 | MET (0.36) | FLT3AXLPDPK1CISD1MET | |
| SCHEMBL5510840 | 0.81 | MET (0.36) | FLT3PDPK1CISD1MET | |
| SCHEMBL5504955 | 0.80 | KMT2A (0.43) | MET | |
| SCHEMBL5506217 | 0.79 | MAPK1 (0.35) | PDPK1MET | |
| SCHEMBL14437291 | 0.79 | CISD1 (0.39) | AAK1CISD1 | |
| SCHEMBL5507768 | 0.78 | CLK4 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063791-A1 | (Spirocyclylamido)aminothiophene compounds | OSI PHARMACEUTICALS, INC. | 2006-03-23 | — | — | US | claimed |
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1797085-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. Hoffmann-Roche AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CHEN LI | 2006-03-23 | — | — | US | disclosed |
| US-20060063791-A1 | (Spirocyclylamido)aminothiophene compounds | OSI PHARMACEUTICALS, INC. | 2006-03-23 | — | — | US | disclosed |
| WO-2006029861-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063791-A1 | (Spirocyclylamido)aminothiophene compounds | KIT, BRDT, MALT1 | FLT3 34/4885AAK1 1203/4885AXL 570/4885 |
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CDK1, CDK14, CDK17 | FLT3 263/4885AAK1 2322/4885AXL 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.